Navigation Links
Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment
Date:11/24/2008

NEW BRUNSWICK, N.J., Nov. 24 /PRNewswire-USNewswire/ -- James M. Golubieski, president of Foundation Venture Capital Group, LLC, a New Jersey Health Foundation affiliate, announced today that the company has made a $500,000 commitment to Longevica Pharmaceuticals, Inc., a company involved in developing kinase inhibitors that may keep normal cells healthy during chemotherapy or radiation treatments.

The company is a start-up at the University of Medicine and Dentistry of New Jersey.

"Despite the tremendous progress in chemotherapy and radiation use to treat cancer patients, most of the drugs available today are extremely toxic, not only killing cancer cells but also killing normal cells," explained Alexey Ryazanov, PhD, founder and president of Longevica. "Our company is working to develop approaches to help protect normal tissue during chemotherapy and radiation treatment."

Longevica scientists discovered that if the EF2 kinase (a protein involved in the regulation of protein synthesis in human cells) can be rendered inactive, normal cells could be protected from dying during chemotherapy and radiation treatment. Not only does this process protect normal tissues from dying, says Dr. Ryazanov, but it also renders the cancer-killing treatment more effective.

"The work of Dr. Ryazanov and the scientists at Longevica is so exciting because currently, there is no such therapy available," explained George F. Heinrich, MD, vice chair and CEO of Foundation Venture Capital Group. "A breakthrough in the use of this kinase could positively affect millions of people undergoing cancer treatments. We are proud that Foundation Venture Capital Group is able to help move Longevica's research to the next level of study."

In addition to helping cancer patients undergoing treatment, preliminary studies also indicate the same drug can be used to help patients who have had strokes by protecting cells and tissues from cell death in the heart and brain. It may also prevent the progressive loss of neurons in patients with Alzheimer's or Parkinson's disease

Foundation Venture Capital Group was founded in 2006 to invest in commercially viable new start-up companies developing technology at the University of Medicine & Dentistry of New Jersey. Longevica Pharmaceuticals, Inc., is its third investment.


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Patient Safety Foundation Partners with Vocera Communications
2. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
5. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. The Tug McGraw Foundation Announces 2007 Fundraising Gala
8. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
9. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
10. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
11. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering ... risks, Novus Medical Detox Center —a leading Florida-based drug treatment facility—advises ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... (AAC) event, will be held at the Bellagio Hotel in Las Vegas, NV ... Social Work (NASW) will be co-hosting the event. , This year’s conference will ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... Analytics EVP and GM Jim Callandrillo and Duane Reed, VP of business ... Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 Acquisition Expands ... Product Development Capabilities in North America ... . Indegene ( http://www.indegene.com ), ... acquisition of Skura Corporation,s life science business. Skura,s ... sales enablement technology for life science organizations and ...
(Date:4/29/2016)... India , April 29, 2016 ... the life science laboratory due to the growing demands ... by advance technology, contemporary automated systems are already adept ... performed by slow, tedious and manual labor. Instrumentation continues ... were not even conceivable just a few years ago. ...
(Date:4/28/2016)... DUBLIN , April 28, 2016 ... the "Global Plastic Surgery Products Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , The global plastic ... CAGR of 9.47% during the period 2016-2020. , ,The ... factor leading to the growth of the market. Lasers ...
Breaking Medicine Technology: